Chart Industries Inc. (“Chart”), now the largest manufacturer of cryogenic storage devices in the world, began manufacturing storage tanks for the cattle breeding industry in the early 1960s. They have since evolved to manufacture storage tanks for liquefied gases up to 100,000 gallons, liquid natural gas systems and liquid CO2 systems.
Buzz Bies, Vice President and General Manager of Cold Storage at Chart first learned about ARMI | BioFabUSA by reading an article in the Union Leader, and immediately saw an opportunity to engage. “The goals of ARMI align with the future of medicine that Chart’s MVE Products support. The ability to treat disease instead of treating symptoms will change medicine forever. Manufacturing of tissues and organs will provide patients with cures that are specifically tailored to their unique system makeup,” he said.
Chart MVE is currently a world leader in manufacturing vacuum insulated products and cryogenic freezer systems. Chart has created the world’s first and only variable temperature freezer with an operating temperature range that varies from -20°C to -196°C. The newest addition to Chart MVE’s stainless steel tank line is the Chart MVE Fusion, which provides long-term dry storage using minimal liquid nitrogen and electricity for up to 31,200 1mL/2mL vials. Once initially charged, Fusion maintains the desired temperature profile with little or no additional liquid nitrogen.
Chart’s vision is to provide cold storage solutions that enable research and regenerative manufacturing to be conducted in a manner that frees organizations from infrastructure requirements that hamper medical progress. When asked, Bies said, “Facilities should be designed to fulfill their purpose. By providing products with reduced electrical, HVAC and nitrogen supply requirements, we allow efficiency and treatment development to more freely drive the process. We also have a number of products in development to be introduced over the next few years that will continue to help the biological manufacturing and storage industries.”
As experts in cold storage, Chart hopes that it can be a resource to assist members of the ARMI | BioFabUSA ecosystem with opportunities in the space, and to partner where appropriate to address unmet needs. Additionally, Chart hopes that through ARMI, they can assist in the progress made in the field by better understanding the requirements of the regenerative medicine industry as it grows and evolves, allowing Chart to continue to create products that are unique and target specific needs.
Bies believes that ARMI | BioFabUSA provides the structure to bring together research and commercialization in a way that is not addressed in the industry. “ARMI goes beyond how a typical medical industry group operates. ARMI actually drives the development with regular project calls. Additionally, the guidance that ARMI is able to give start-ups and companies with new innovations to navigate FDA requirements through consulting opportunities afforded by Dr. Richard McFarland are very unique. We are excited to have the opportunity to be a part of ARMI and the future of medicine.”